BIOVF: AI 评分 56/100 — AI 分析 (4月 2026)

Swedish Orphan Biovitrum AB (publ) (Sobi) is a biopharmaceutical company focused on providing treatments for rare diseases and specialty care. The company operates across haematology, immunology, and specialty care, with a global presence.

Key Facts: AI Score: 56/100 Sector: Healthcare

公司概况

概要：

Swedish Orphan Biovitrum AB (publ) (Sobi) is a biopharmaceutical company specializing in haematology, immunology, and specialty care, offering treatments for rare diseases across Europe, North America, the Middle East, Asia, and Australia. With a focus on innovative therapies, Sobi addresses unmet medical needs in niche markets, maintaining a $14.70B market capitalization.

BIOVF是做什么的？

Swedish Orphan Biovitrum AB (publ), also known as Sobi, was founded in 1939 and is headquartered in Stockholm, Sweden. The company has evolved into a global biopharmaceutical leader focused on rare diseases and specialty care. Sobi operates through three primary segments: Haematology, Immunology, and Specialty Care. Its product portfolio includes Alprolix and Elocta/Eloctate for haemophilia, Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria, Doptelet for thrombocytopenia, Gamifant for hemophagocytic lymphohistiocytosis, Kineret for various inflammatory conditions, Orfadin for hereditary tyrosinemia type 1 and alkaptonuria, Synagis for respiratory syncytial virus prevention in infants, VONJO for myelofibrosis, and Zynlonta for lymphoma. Sobi also provides other medicines like Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra. The company collaborates with partners like Sanofi, Apellis Pharmaceuticals, ADC Therapeutics, and Cartesian Therapeutics to develop and commercialize innovative therapies. Sobi's global presence extends across Europe, North America, the Middle East, Asia, and Australia, reflecting its commitment to addressing unmet medical needs worldwide.

BIOVF的投资论点是什么？

Swedish Orphan Biovitrum AB (publ) presents a focused investment opportunity within the rare disease and specialty care biopharmaceutical sector. With a market capitalization of $14.70B and a gross margin of 78.9%, Sobi demonstrates financial stability. Key value drivers include the continued growth of its haematology and immunology portfolios, particularly Alprolix, Elocta/Eloctate, and Aspaveli/Empaveli. Upcoming catalysts include potential regulatory approvals for new indications and expansion into new geographic markets. However, investors should be aware of risks such as competition from biosimilars and potential setbacks in clinical trials. The company's ROE of 1.2% and profit margin of 1.7% suggest areas for improvement in operational efficiency.

BIOVF在哪个行业运营？

Swedish Orphan Biovitrum AB (publ) operates within the specialty and generic drug manufacturing industry, characterized by intense competition, stringent regulatory requirements, and high R&D costs. The market for rare disease treatments is growing, driven by increased awareness, improved diagnostics, and regulatory incentives. Key competitors include companies like Sanofi and Apellis Pharmaceuticals. Sobi's focus on haematology, immunology, and specialty care positions it to capitalize on the increasing demand for innovative therapies in these areas. The global biopharmaceutical market is expected to continue its growth trajectory, driven by aging populations and advancements in medical technology.

Drug Manufacturers - Specialty & Generic

Healthcare

BIOVF有哪些增长机遇？

Expansion of Haematology Portfolio: Sobi can further expand its haematology portfolio by developing and commercializing new treatments for haemophilia and other blood disorders. The global market for haemophilia treatment is projected to reach $14.5 billion by 2028. Sobi's existing products, Alprolix and Elocta/Eloctate, provide a strong foundation for continued growth in this area. Success hinges on regulatory approvals and market penetration in key geographies.
Growth in Immunology Segment: Sobi's immunology segment, driven by Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria (PNH), presents a significant growth opportunity. The PNH market is expected to grow as awareness and diagnosis improve. Sobi can capitalize on this trend by expanding the availability of Aspaveli/Empaveli and developing new therapies for other immunological disorders. The timeline for realizing this growth depends on clinical trial outcomes and regulatory approvals.
Geographic Expansion: Sobi has the opportunity to expand its geographic footprint, particularly in emerging markets. These markets offer significant growth potential due to increasing healthcare spending and unmet medical needs. Sobi can leverage its existing product portfolio and partnerships to enter new markets and establish a presence. This expansion strategy requires careful market analysis and strategic partnerships to navigate local regulations and distribution channels.
Strategic Collaborations and Acquisitions: Sobi can pursue strategic collaborations and acquisitions to expand its product pipeline and therapeutic expertise. Collaborating with other biopharmaceutical companies and research institutions can accelerate the development of new therapies and broaden Sobi's portfolio. Acquisitions can provide access to new technologies, products, and markets. These strategic moves can enhance Sobi's long-term growth prospects and competitive position.
Development of Novel Therapies: Investing in the research and development of novel therapies for rare diseases and specialty care is crucial for Sobi's long-term growth. By focusing on innovative treatments that address unmet medical needs, Sobi can differentiate itself from competitors and capture market share. This requires a strong R&D pipeline, strategic partnerships, and a commitment to scientific excellence. The timeline for realizing this growth depends on the success of clinical trials and regulatory approvals.

Market Cap of $14.70B reflects Sobi's significant presence in the biopharmaceutical industry.
Gross Margin of 78.9% indicates strong pricing power and efficient cost management.
Debt-to-Equity Ratio of 30.47 suggests a balanced capital structure.
Profit Margin of 1.7% indicates potential for improvement in operational efficiency.
Beta of 0.23 suggests lower volatility compared to the overall market.

BIOVF提供哪些产品和服务？

Develops and commercializes treatments for rare diseases.
Offers therapies in haematology, immunology, and specialty care.
Provides Alprolix and Elocta/Eloctate for haemophilia A and B.
Offers Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria.
Provides Doptelet for the treatment of immune thrombocytopenia.
Offers Gamifant for treating hemophagocytic lymphohistiocytosis.
Develops drug substances for ReFacto AF/Xyntha for Pfizer.

BIOVF如何赚钱？

Develops and manufactures specialized pharmaceuticals.
Commercializes and distributes its products globally.
Collaborates with other companies for research and development.
Focuses on niche markets with high unmet medical needs.

Patients with rare diseases and specialty care needs.
Hospitals and clinics that treat these patients.
Healthcare providers who prescribe Sobi's medications.
Distributors and pharmacies that supply Sobi's products.

Specialized product portfolio focused on rare diseases.
Strong relationships with healthcare providers and patient advocacy groups.
Intellectual property protection for its key products.
Global distribution network and commercial infrastructure.

什么因素可能推动BIOVF股价上涨？

Upcoming: Potential regulatory approvals for new indications of existing products.
Ongoing: Expansion of Aspaveli/Empaveli into new markets.
Ongoing: Continued growth in the haematology portfolio.
Upcoming: Results from ongoing clinical trials for novel therapies.
Ongoing: Strategic collaborations and acquisitions to expand product pipeline.

BIOVF的主要风险是什么？

Potential: Competition from biosimilars and generic drugs.
Potential: Regulatory challenges and pricing pressures.
Potential: Clinical trial failures and product recalls.
Ongoing: Dependence on key products for revenue.
Ongoing: Economic downturns and healthcare reforms.

BIOVF的核心优势是什么？

Specialized product portfolio in rare diseases.
Global presence and distribution network.
Strong partnerships with other pharmaceutical companies.
Focus on innovative therapies and unmet medical needs.

BIOVF的劣势是什么？

Limited product diversification.
Dependence on key products for revenue.
Relatively small size compared to major pharmaceutical companies.
Lower profit margin compared to industry peers.

BIOVF有哪些机遇？

Expansion into new therapeutic areas and geographic markets.
Strategic collaborations and acquisitions.
Development of novel therapies for rare diseases.
Increasing awareness and diagnosis of rare diseases.

BIOVF面临哪些威胁？

Competition from biosimilars and generic drugs.
Regulatory challenges and pricing pressures.
Clinical trial failures and product recalls.
Economic downturns and healthcare reforms.

BIOVF的竞争对手是谁？

Sanofi — Major pharmaceutical company with a broad range of products. — (SNY)
Apellis Pharmaceuticals, Inc. — Focuses on complement-targeted therapies. — (APLS)

Key Metrics

MoonshotScore: 56/100

Company Profile

Headquarters: Stockholm, Sweden
Employees: 1,888

AI Insight

AI analysis pending for BIOVF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (publ) (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for rare diseases and specialty care. Sobi focuses on haematology, immunology, and specialty care, offering treatments for conditions like haemophilia, paroxysmal nocturnal haemoglobinuria, and immune thrombocytopenia. The company's business model involves developing, manufacturing, and commercializing specialized pharmaceuticals, often targeting niche markets with high unmet medical needs. Sobi collaborates with other companies for research and development, expanding its product pipeline and therapeutic expertise. With a global presence, Sobi distributes its products to patients, hospitals, and healthcare providers worldwide.

What do analysts say about BIOVF stock?

Analyst coverage of Swedish Orphan Biovitrum AB (publ) (BIOVF) is pending, but key valuation metrics include a market capitalization of $14.70B and a gross margin of 78.9%. Growth considerations revolve around the company's ability to expand its product portfolio, penetrate new markets, and navigate regulatory challenges. Investors should monitor the company's financial performance, clinical trial results, and strategic initiatives to assess its long-term growth potential. The company's ROE of 1.2% and profit margin of 1.7% suggest areas for improvement in operational efficiency.

What are the main risks for BIOVF?

Swedish Orphan Biovitrum AB (publ) (BIOVF) faces several risks inherent to the biopharmaceutical industry. Competition from biosimilars and generic drugs poses a threat to its revenue stream. Regulatory challenges and pricing pressures can impact the profitability of its products. Clinical trial failures and product recalls can disrupt its operations and damage its reputation. The company's dependence on key products for revenue concentration also presents a risk. Additionally, economic downturns and healthcare reforms can affect the demand for its products and services.